Hundreds of Nashville-Area Kids Receive Free Dental Screenings, Shoes, and More at 2025 Kids Dental Day
NASHVILLE, Tenn., July 21, 2025--(BUSINESS WIRE)--Hundreds of children from across Middle Tennessee recently received free dental screenings, new shoes, hygiene kits, books, and more during the 4th annual Kids Dental Day at First Horizon Park. Hosted by Delta Dental of Tennessee, the Nashville Sounds, and cityCURRENT, the event brought together 250 children and over a dozen community organizations to provide essential health services and school readiness resources to area youth.
"This is one of our favorite days of the year," said Adam English, General Manager and Chief Operating Officer of the Nashville Sounds. "First Horizon Park is meant to be a place where families can come together, and thanks to our incredible partners, we're able to make a real impact for hundreds of kids in our community."
Tooth decay is the most common chronic condition of childhood, and poor oral health can affect a child's quality of life, performance at school, and success later in life. According to the CDC's 2024 Oral Health Surveillance Report, half of all children aged 6 to 9 have had cavities in their primary or permanent teeth. Left untreated, these cavities can lead to pain, infections, and missed school days - and affect a child's ability to eat, speak, play, and learn. Events like Kids Dental Day help bridge the gap in access to care and put children on a path toward healthier, more confident futures.
"We're always grateful to the Sounds and our many community partners and volunteers who come together to make Kids Dental Day such a success," said Jeff Ballard, President and CEO of Delta Dental of Tennessee. "It's a fun, high-impact day that helps make care more accessible - and reminds kids that their health and happiness matter."
The 250 participating kids arrived throughout the day from summer camps and community programs that coordinated with event organizers, including Preston Taylor Ministries and local chapters of the Boys and Girls Club of Middle Tennessee. Kids received free dental screenings and dental cleanings (as needed), a new pair of socks and shoes, snacks, and a new book. About 25% of children receiving cleanings also had signs of developing cavities that the dental team was able to treat with silver diamine fluoride (SDF), a non-invasive treatment used to stop the growth of tooth decay.
"Helping kids access quality dental care is at the heart of our mission," said Dr. Michele Blackledge-Polk, Director of Oral Health at Neighborhood Health. "Good oral health habits start early and set the foundation for lifelong health, confidence, and success. One of the most powerful aspects of events like Kids Dental Day is our ability to assess the state of children in the community by having limited exams and education on brushing and flossing. Silver Diamine Fluoride is a new tool that works by preventing the progression of cavities. When properly used, we can reduce the need for drilling and hopefully the number of visits required to treat the tooth. This event is all about meeting families where they are and making oral health approachable and fun."
The day also featured educational stations and activities to engage children as they prepare to return to school in the coming weeks. Book'em brought their Book Bus, giving every child the opportunity to pick out a free book to take home. The American Heart Association provided hands-only CPR demonstrations, and the Adventure Science Center hosted STEM activities. PBS Kids on Nashville PBS gave out temporary tattoos featuring characters from the Delta Dental and Smile180 Foundation supported oral health education programming.
"For many of our families, back-to-school can be extremely time-consuming and stressful," said Dwight Johnson, Executive Director at Preston Taylor Ministries. "Kids Dental Day helps to alleviate a lot of that burden with care, joy, and community. Our students left with healthier smiles, fresh shoes, and a boost of confidence for the year ahead."
130 volunteers from cityCURRENT and other community groups helped make the day run smoothly ─ from assisting families and guiding kids through activities to distributing books, snacks, and dental kits.
"Kids Dental Day is a shining example of what can happen when the business community comes together with a shared purpose," said Kelly Meyers, Nashville Market President, cityCURRENT. "It's more than a day of service ─ it's a reminder to each child that they matter, and we're here to support them."
Additional partners helped to make the event possible behind the scenes. Signature Transportation provided buses to bring kids to and from summer programs and camps across the region, ensuring that transportation was never a barrier to participation. Volunteers stayed energized thanks to snacks and drinks donated by Kroger, as well as coffee and doughnuts donated by Dunkin' Donuts. Dental supplies were donated by Henry Schein and equipment was provided by Hope Smiles.
To learn more about Kids Dental Day, visit: deltadentaltn.com/kids-dental-day.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250720257432/en/
Contacts
Ann Waller Curtis / annwaller.curtis@stonesrivergroup.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
Community Health Systems, Inc. Announces Increase in Tender Cap for 5.625% Senior Secured Notes Due 2027
FRANKLIN, Tenn., July 28, 2025--(BUSINESS WIRE)--Community Health Systems, Inc. (the "Company") (NYSE: CYH) today announced that its wholly owned subsidiary, CHS/Community Health Systems, Inc. (the "Issuer"), has increased the principal amount of the Issuer's approximately $1,757 million aggregate principal amount outstanding 5.625% Senior Secured Notes due 2027 (the "2027 Notes") that it can repurchase under its previously announced cash tender offer (the "Tender Offer") from $1,470 million to $1,757 million, on the terms and subject to the conditions set forth in the Issuer's Offer to Purchase dated July 28, 2025 (the "Offer to Purchase"). Consistent with amending the Tender Cap, the Issuer has amended the financing condition of the Tender Offer to provide that the Issuer's obligation to accept for purchase, and to pay for, 2027 Notes validly tendered and not validly withdrawn is subject to the satisfaction or waiver of certain conditions, including, among other things, the condition that the Issuer has completed a debt financing on terms and conditions satisfactory to it yielding gross cash proceeds of $1,790 million or more. The complete terms and conditions of the Tender Offer is set forth in the Offer to Purchase. The Issuer has retained Citigroup Global Markets Inc. to act as dealer manager in connection with the Tender Offer. Questions about the Tender Offer may be directed to Citigroup Global Markets Inc. at (800) 558-3745 (toll free) or (212) 723-6106 (collect). Copies of the Tender Offer documents and other related documents may be obtained from Global Bondholder Services Corporation, the depositary and information agent for the Tender Offer, at (855) 654-2015 (toll free) or (212) 430-3774 (collect) or email contact@ The Tender Offer is being made solely by means of the Tender Offer documents. Under no circumstances shall this press release constitute an offer to purchase or sell or the solicitation of an offer to purchase or sell the 2027 Notes or any other securities of the Issuer or any other person, nor shall there be any offer or sale of any 2027 Notes or other securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In addition, nothing contained herein constitutes a notice of redemption of the 2027 Notes. No recommendation is made as to whether holders of the 2027 Notes should tender their 2027 Notes. Forward-Looking Statements This press release may include information that could constitute forward-looking statements. These statements involve risk and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law. View source version on Contacts Investor Contacts: Kevin J. Hammons, 615-465-7000President and Chief Financial OfficerorAnton Hie, 615-465-7012Vice President – Investor Relations Media Contact: Tomi Galin, 615-628-6607Executive Vice President, Corporate Communications, Marketing and Public Affairs
Yahoo
19 hours ago
- Yahoo
'Immense loss': High school football player dies from heat stroke
A high school football player in Tennessee has died after suffering complications from a heat stroke, according to his family. Joshua Henderson, 16, died on Saturday due to "complications from organ failure caused by a severe heat stroke," despite "bravely fighting for his life in the hospital," his family noted in their GoFundMe. His aunt, Kristen Henderson, told ABC News that he was hospitalized on July 6, when he passed out at football practice. Shortly after dropping Henderson off at practice, his mother received a call to say he was unresponsive, according to his aunt. When she got there, he was rushed to the hospital, his aunt said. Henderson, who was a student and football player for Bolton High School in Arlington, Tennessee, was described as as an "exceptional athlete and dedicated scholar," Memphis Shelby County Schools said in a statement on Monday. MORE: Heat stroke vs. heat exhaustion: Safety tips as dangerous temperatures hit US "His kindness, determination and positive spirit left a lasting impression on classmates, teachers and our entire BHS community," school officials said. "We extend our deepest sympathies to his family, friends and all those grieving this immense loss." He was "deeply loved by his parents, siblings, extended family and all who knew him," his family noted in a statement. "His sudden loss has left our hearts shattered and our world forever changed. Joshua's life, though short, was meaningful and full of light," the family said. Kristen Henderson, who described her nephew as a "gentle giant," said he had been playing offensive and defense line on the football team and was being scouted by different universities "because he was so good." MORE: Heat indices could hit 120 as sweltering temperatures grip eastern half of US Henderson, who was about to be a senior in high school this fall, wanted to attend the University of Florida on a football scholarship and pursue a degree in engineering, his aunt said. School officials said grief counselors and support staff will be available at the high school "in the coming days for any student or staff member who needs them." Extreme heat is the deadliest weather-related hazard in the U.S., claiming roughly 2,000 people annually, according to data from the Centers for Disease Control and Prevention. The latest CDC statistics show that 150 heat-related deaths have already occurred in the United States in 2025. For tips on how to stay safe in a heat wave, click here.
Yahoo
20 hours ago
- Yahoo
iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025
NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August 15, 2025 at 4:00 PM ET featuring Anthony Langone, MD (Associate Professor of Medicine, Division of Nephrology and Hypertension, Vanderbilt University). To register, click here. Dr. Langone, who serves as the national principal investigator (NPI) for iMDx's ongoing kidney transplant monitoring trial, will discuss the expanding role of donor-derived cell-free DNA (dd-cfDNA) in transplant care, patient management, and the benefits of enabling in-house testing. In addition, the Company's management team will provide an overview of their kitted strategy, and the uniqueness of their GraftAssure™-branded in-house testing option. The GraftAssure™ family of assays, already available in lab-developed test form and as research-use-only kits, leverages advanced digital PCR (dPCR) technology to deliver highly quantitative, reliable dd-cfDNA results for transplant monitoring. The Company is developing a diagnostics test kit for clinical use, to enable hospitals to run their own tests, in-house. A live question and answer session will follow the formal presentations. Those who are registered but unable to attend the virtual event live may send questions in advance of the event to questions@ Please send your questions at least 12 hours in advance of the event. About Anthony Langone, MD Anthony Langone, MD is an Associate Professor of Medicine in the Division of Nephrology and Hypertension within the Department of Medicine at Vanderbilt University Medical Center. He received his undergraduate degree from Cornell University where he graduated with honors. He completed his medical degree at the State University of New York at Buffalo School of Medicine and completed his residency at Baylor College of Medicine where he graduated AOA and with the McIntosh award, top resident honors. He completed general and renal transplantation fellowships at Vanderbilt, and was elected chief fellow in 2001. Dr. Langone's clinical focus is on kidney and pancreas transplantation, amyloidosis and multiple myeloma. His research interests include ameliorating drug side effects and new drug and biomarker discovery. His professional activities include being an active member of the DCE Committee, the Nephrology Fellowship Clinical Competency Committee, a renal representative and founding member of the Vanderbilt Amyloidosis Multidisciplinary Program (VAMP), and the Medical Director of Medical Specialties Clinic. Dr. Langone is a Fellow of the American Society of Transplantation (FAST) and a member of the American Society of Nephrology (ASN). He is an active participant in multiple American Society of Transplantation Community of Practices (COPs). About iMDx Transplant Products and Product Candidates in Development The company's flagship transplant technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company's scientists in Germany and the U.S. have played a critical role over the past decade in developing the science that helped establish dd-cfDNA as a trusted biomarker of transplant rejection, and iMDx is now commercializing that technology using a market disruptive approach. Its transplant diagnostics under the GraftAssure™ brand include the following: GraftAssureCore – The company's lab-developed test (LDT), currently reimbursed by CMS and performed at its CLIA-certified laboratory in Nashville. The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. For purposes of this press release, references to 'GraftAssureCore' shall be deemed to include the test previously marketed as VitaGraft. GraftAssureIQ – A research-use-only (RUO) kit intended for non-clinical applications and clearly labeled as such. GraftAssureDx – The in vitro diagnostic (IVD) kit currently in development for use in clinical decision-making, which the company intends to submit for FDA authorization. About Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Inc., or iMDx, formerly Oncocyte Corp. (OCX), is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. iMDx™, GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, and VitaGraft™ are trademarks of Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics (Nasdaq: IMDX) moved its headquarters from Irvine, Calif., to Nashville, Tenn., in June 2025. The company's new NASDAQ symbol became effective June 18. Investors may visit for more information. Forward-Looking Statements Any statements that are not historical fact (including, but not limited to, statements that contain words such as 'will,' 'believes,' 'plans,' 'anticipates,' 'expects,' 'estimates,' 'may,' and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, expected regulatory approval(s) and commercial launch, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of iMDx's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic iMDx or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of iMDx, particularly those mentioned in the 'Risk Factors' and other cautionary statements found in iMDx's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. iMDx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investor Contact: Doug Farrell LifeSci Advisors LLC dfarrell@ in to access your portfolio
